Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 276 of the 278 references it cites were found in a registry or an index.

RAS-targeted therapies: is the undruggable drugged?

Open access
Moore, Amanda R., Rosenberg, Scott C., McCormick, Frank, Malek, Shiva · 2020 · Nature Reviews Drug Discovery

Abstract

RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in cancers, and, consequently, investigators have sought an effective RAS inhibitor for more than three decades. Even 10 years ago, RAS inhibitors were so elusive that RAS was termed ‘undruggable’. Now, with the success of allele-specific covalent inhibitors against the most frequently mutated version of RAS in non-small-cell lung cancer, KRASG12C, we have the opportunity to evaluate the best therapeutic strategies to treat RAS-driven cancers. Mutation-specific biochemical properties, as well as the tissue of origin, are likely to affect the effectiveness of such treatments. Currently, direct inhibition of mutant RAS through allele-specific inhibitors provides the best therapeutic approach. Therapies that target RAS-activating pathways or RAS effector pathways could be combined with these direct RAS inhibitors, immune checkpoint inhibitors or T cell-targeting approaches to treat RAS-mutant tumours. Here we review recent advances in therapies that target mutant RAS proteins and discuss the future challenges of these therapies, including combination strategies. RAS proteins, which are frequently altered in cancer, were once considered undruggable, but compounds targeting some mutant RAS proteins have recently demonstrated clinical efficacy. In this Review, Malek and colleagues explore how these and other drugs that target RAS or associated pathways might be used effectively, particularly in combinations, and d…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41573-020-0068-6

Cites

276 of 276 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 278 references

Research works printed but not linked: 3

  1. Mirati Therapeutics. Mirati Therapeutics Presents First Clinical Data of Phase 1/2 Trial of MRTX849 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ir.mirati.com https://ir.mirati.com/news-releases/news-details/2019/Mirati-Therapeutics-Presents-First-Clinical-Data-Of-Phase-12-Trial-Of-MRTX849-At-The-2019-AACR-NCI-EORTC-International-Conference-On-Molecular-Targets-And-Cancer-Therapeutics/default.aspx (2019).
  2. Revolution Medicines. Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics www.revmed.com https://www.revmed.com/media/revolution-medicines-present-preclinical-data-novel-inhibitors-oncogenic-rason-mutants-aacr (2019).
  3. Merck. Moderna and Merck expand mRNA cancer vaccines collaboration merck.com https://investors.merck.com/news/press-release-details/2018/Moderna-and-Merck-Expand-mRNA-Cancer-Vaccines-Collaboration/default.aspx (Merck, 2018).

Cited by

See all 1,103

Metadata

Authors
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S.
Affiliations
  • Genentech (US)
  • University of California, San Francisco (US)
Corresponding author
Malek, Shiva
Venue
Nature Reviews Drug Discovery
Published
2020-06-11
Volume
19
Issue
8
Pages
533-552
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W3034504519
Cited by
1,103
References
278
Citations by year
2026: 140 · 2025: 185 · 2024: 224 · 2023: 183 · 2022: 197 · 2021: 152 · 2020: 22
FWCI
13.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
National Cancer Institute (R35CA197709)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
Ras, KRAS, NRAS, HRAS, RAS inhibitors, KRAS G12C, RAS-driven cancers, combination therapy, Ras effector pathways, immune checkpoint inhibitors, T cell targeting, non-small cell lung cancer
MeSH terms
Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Drug Delivery Systems, ras Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAS-targeted therapies: is the undruggable drugged? https://app.cochat.ai/papers/10.1038/s41573-020-0068-6
The paper
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020). RAS-targeted therapies: is the undruggable drugged? Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-020-0068-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.